Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants

17. november 2026 oppdatert av: Beijing Suncadia Pharmaceuticals Co., Ltd

A Randomized, Double Blind, Dose Escalation, Placebo Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravenous and Subcutaneous Administrations of SHR 3201 Injection in Healthy Participants

This study is a randomized, double-blind, dose-escalation, placebo-controlled Phase I clinical trial in healthy participants to evaluate the safety, tolerability, and pharmacokinetics of single intravenous and subcutaneous administrations of SHR-3201.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

50

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Anhui
      • Hefei, Anhui, Kina, 230000
        • Rekruttering
        • The First Affiliated Hospital of University of Science and Technology of China
        • Hovedetterforsker:
          • Jiong Shi
        • Hovedetterforsker:
          • Zhaoyi Yang
        • Ta kontakt med:
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 60 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Healthy male or female participants aged 18 to 60 years (inclusive) at the time of informed consent signing;
  2. Male participants weighing ≥ 50.0 kg, and female participants weighing ≥ 45.0 kg, with a body mass index (BMI) between 19.0 and 28.0 kg/m² (inclusive), where BMI = weight (kg) / height² (m²);
  3. Female participants of child bearing potential shall agree to contraception and oocyte donation avoidance from ICF signature to 6 months after last investigational product dose, with negative serum pregnancy tests at screening and baseline. Male participants shall agree to highly effective contraception and sperm donation avoidance from ICF signature to 6 months after last investigational product dose;
  4. Ability to understand the study procedures and requirements, willingness to participate voluntarily, and provide written informed consent.

Exclusion Criteria:

  1. Participants with past or current acute or chronic disorders of the circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric systems or metabolic abnormalities, as assessed by the Investigator to be unsuitable for study enrollment;
  2. Have a history of drug or other allergies, or, in the investigator's judgment, may be allergic to the investigational product or any of its components;
  3. Have undergone major surgery within 6 months prior to screening, or have undergone surgery that may significantly affect the in vivo disposition of the investigational product or the safety evaluation, or plan to undergo surgery during the trial period;
  4. Have participated in any clinical trial as a participant within 3 months prior to Screening, or plan to participate in other clinical trials during the course of this study;
  5. Have experienced blood loss or donated blood > 400 mL (excluding menstrual blood loss in females), received blood transfusion or blood products within 3 months prior to Screening, or plan to donate blood during the trial or within 1 month after the end of the trial;
  6. Cannot tolerate MRI or have MRI contraindications, including but not limited to cardiac pacemaker, defibrillator, artificial heart valve or other metallic implants; or other conditions assessed by the Investigator that may cause potential risks during MRI scanning;
  7. Have any laboratory abnormalities at screening, or have clinically significant abnormalities in vital signs, physical examinations, or laboratory tests specified in the protocol as judged by the investigator;
  8. Have chest X-ray (posteroanterior view) or abdominal ultrasound findings at Screening judged by the investigator to be clinically significant abnormalities;
  9. Have positive results at Screening for any of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), or Treponema pallidum antibody (Anti-TP);
  10. Have used or are currently using any prescription drugs or over-the-counter (OTC) medications within 2 weeks prior to dosing; or have taken functional vitamins, health supplements, or herbal products; or are known to require other medication during the trial period;
  11. Have consumed excessive amounts of tea, coffee, or caffeinated beverages (average > 8 cups per day, 200 mL per cup) within 3 months prior to screening;
  12. Have consumed special foods (e.g., grapefruit, grapefruit juice, or food/beverages containing grapefruit juice, chocolate, tobacco, alcohol, caffeinated products, etc.) within 48 hours prior to dosing;
  13. Have a history of regular alcohol consumption (i.e., > 14 standard units per week within 3 months prior to Screening, where 1 standard unit contains 14 g of alcohol, equivalent to 285 mL of beer, 25 mL of 40% spirit, or 85 mL of wine), or are unable to abstain from alcohol during the trial; or have a positive alcohol breath test;
  14. Have an average daily smoking history of > 5 cigarettes per day within 3 months prior to Screening, or are unable to abstain from smoking during the trial;
  15. Have a history of drug abuse or substance use; or have a positive result on drug abuse screening (including MDMA, methamphetamine, morphine, ketamine, and THC acid);
  16. Are pregnant or lactating females;
  17. Have difficulty with venous blood sampling, are unable to tolerate venipuncture, or have a history of needle or blood phobia;
  18. Participants who, in the opinion of the investigator, may be unable to complete the study for other reasons, or who are considered unsuitable for enrollment by the investigator.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Dose 1 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 1.

SHR 3201 injection.

SHR 3201 placebo.

Eksperimentell: Dose 2 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 2.

SHR 3201 injection.

SHR 3201 placebo.

Eksperimentell: Dose 3 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 3.

SHR 3201 injection.

SHR 3201 placebo.

Eksperimentell: Dose 4 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 4.

SHR 3201 injection.

SHR 3201 placebo.

Eksperimentell: Dose 5 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 5.

SHR 3201 injection.

SHR 3201 placebo.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Adverse events (AEs)
Tidsramme: From pre-dose to 36 days post-dose.
From pre-dose to 36 days post-dose.

Sekundære resultatmål

Resultatmål
Tidsramme
Serum concentration of SHR-3201 after single-dose administration
Tidsramme: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Area Under the Concentration (AUC) of SHR-3201 after single administration (AUC0-last, AUC0-inf)
Tidsramme: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Time to peak concentration (Tmax)
Tidsramme: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Peak concentration (Cmax)
Tidsramme: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Elimination half-life (T1/2)
Tidsramme: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Clearance (CL)
Tidsramme: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Steady-state volume of distribution (Vss)
Tidsramme: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Bioavailability of SHR-3201 following subcutaneous administration
Tidsramme: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Incidence of anti-drug antibodies (ADA)
Tidsramme: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. november 2026

Primær fullføring (Antatt)

1. januar 2027

Studiet fullført (Antatt)

1. februar 2027

Datoer for studieregistrering

Først innsendt

16. oktober 2026

Først innsendt som oppfylte QC-kriteriene

16. oktober 2026

Først lagt ut (Faktiske)

22. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • SHR-3201-101

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .